CreativeNature R.Zwerver / Shutterstock.com
A US court has ruled that biotechnology company Regeneron engaged in “inequitable conduct” after finding that it withheld information from a patent application for a genetically modified mouse.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Regeneron; Merus; US District Court for the Southern District of New York; patent; genetically modified mouse